develop
countri
vaccin
manufactur
network
dcvmn
conven
intern
meet
coorganis
queen
saovabha
memori
institut
qsmi
bionet
asia
auspic
thai
red
cross
societi
nearli
profession
work
research
develop
manufactur
suppli
vaccin
countri
gather
bangkok
dcvmn
largest
allianc
corpor
manufactur
suppli
vaccin
type
variou
present
immunis
programm
contribut
significantli
global
public
health
effort
erad
polio
elimin
control
spread
known
emerg
infecti
diseas
around
world
local
health
author
global
health
organis
repres
meet
includ
unit
nation
intern
dcvmn
improv
qualiti
life
everi
child
famili
commun
global
prof
khomvilai
invit
dr
jm
okwobel
director
speak
achiev
challeng
global
vaccin
action
plan
gvap
jm
okwobel
highlight
achiev
global
immunis
polio
erad
close
two
countri
current
report
wild
polioviru
measl
vaccin
reduc
diseas
region
mening
epidem
elimin
africa
half
popul
vaccin
around
million
death
avert
vaccin
still
challeng
remain
limit
vaccin
afford
suppli
failur
healthcar
integr
disrupt
immunis
geopolit
conflict
poorqual
health
data
result
stagnant
coverag
repeat
failur
reach
immunis
goal
instanc
million
children
miss
dose
dtp
eastern
mediterranean
region
mostli
securitycompromis
countri
solut
expect
manufactur
includ
measur
assur
control
temperatur
chain
ctc
coldchain
facil
lack
implement
improv
deliveri
technolog
eas
use
field
assist
reduc
risk
shortag
monitor
account
framework
gvap
identifi
respond
immunis
challeng
batson
chief
strategi
offic
path
provid
overview
develop
vaccin
market
past
decad
demand
highervalu
vaccin
grown
antigen
incorpor
multival
combin
vaccin
pentaval
vaccin
replac
dtp
mmrmr
replac
measl
vaccin
new
complex
vaccin
introduc
robust
vaccin
develop
pipelin
emerg
industrialis
develop
countri
latter
serum
institut
india
mening
vaccin
reach
million
peopl
anticip
japanes
enceph
vaccin
chengdu
institut
china
reach
million
peopl
dcvmn
member
play
essenti
role
global
vaccin
suppli
contribut
improv
health
drive
new
market
divers
term
ownership
state
privat
scale
portfolio
market
local
provid
emerg
new
multin
compani
fig
import
understand
role
plan
anticip
chang
global
versu
nation
financ
procur
vaccin
chunsuttiwat
ministri
public
health
thailand
discuss
health
secur
sustain
develop
goal
sdg
thailand
introduc
univers
health
insur
coverag
uhc
reach
insur
coverag
region
associ
southeast
asian
nation
asean
repres
world
popul
initi
collabor
region
vaccin
secur
selfreli
seek
understand
vaccin
need
asean
countri
perspect
identifi
area
cooper
challeng
harmonis
regulatori
pathway
improv
access
vaccin
develop
countri
discuss
ward
increas
regulatori
converg
region
intern
level
achiev
adopt
common
standard
practic
vaccin
regul
without
requir
harmonis
law
converg
andor
dtp
diphtheria
tetanu
pertussi
combin
vaccin
tion
need
implement
consist
intent
succeed
role
promot
access
qualiti
medic
product
develop
norm
standard
promot
regulatori
converg
harmonis
initi
benefit
challeng
identifi
effici
collabor
among
regul
foster
incountri
regulatori
decis
support
collabor
replac
duplic
h
deehan
unicef
brief
audienc
prevent
remedi
strategi
manag
vaccin
suppli
constraint
unicef
procur
suppli
vaccin
countri
need
assist
vaccin
programm
increas
significantli
year
sinc
dose
procur
annual
supplier
develop
countri
recent
suppli
constraint
includ
bcg
yellow
fever
vaccin
ipv
vaccin
support
polio
endgam
strategi
earli
transpar
commun
manufactur
close
monitor
stock
level
within
countri
requir
allow
prompt
mitig
action
ultim
reduc
risk
interrupt
suppli
deehan
invit
dcvmn
member
work
unicef
achiev
sustain
global
suppli
afford
vaccin
assur
qualiti
malham
head
market
shape
gavi
present
gavi
recent
accomplish
activ
pentaval
pneumococc
rotaviru
vaccin
steadili
introduc
grow
number
countri
surpass
gavi
expect
volum
vaccin
dcvm
continu
grow
although
valu
vaccin
procur
dcvm
remain
rel
low
secur
global
suppli
gavi
foster
procur
multipl
countri
manufactur
fig
b
term
activ
gavi
introduc
two
major
chang
cofinanc
polici
link
cofinanc
price
countri
transit
phase
ii
develop
payment
plan
help
countri
get
default
gavi
strateg
goal
includ
vaccin
goal
acceler
equit
uptak
coverag
vaccin
health
system
goal
increas
effect
effici
immunis
deliveri
part
strengthen
health
system
financ
goal
improv
sustain
nation
immunis
program
marketshap
goal
shape
market
vaccin
immunis
product
goal
gavi
hope
immunis
million
addit
children
around
world
end
rodriguez
paho
revolv
fund
vaccin
procur
took
moment
celebr
america
region
success
first
region
elimin
rubella
enabl
commit
member
countri
region
goal
paho
revolv
fund
vaccin
manufactur
outlin
challeng
face
vaccin
shortag
strategi
overcom
latin
american
popul
threat
yellow
fever
viru
vaccin
demand
exce
number
dose
avail
annual
million
avoid
suppli
shortag
countri
need
concret
demand
plan
secur
budget
vaccin
purchas
care
stock
manag
prevent
shortag
start
countri
level
paho
act
region
facilit
time
suffici
suppli
vaccin
manufactur
worldwid
essenti
assur
global
suppli
steel
bill
melinda
gate
foundat
emphasis
import
address
global
challeng
diarrheal
diseas
vaccin
intern
partnership
global
fund
product
develop
partnership
dcvm
alreadi
deliv
two
vaccin
prevent
lead
caus
diarrheal
mortal
demonstr
power
partnership
first
cholera
vaccin
develop
partnership
vabiotech
shantha
biotechn
ivi
vaccin
prequalifi
wide
utilis
countri
endem
cholera
second
rotaviru
vaccin
develop
partnership
bharat
biotech
indian
depart
biotechnolog
path
vaccin
licens
india
introduct
earli
dossier
readi
prequalif
c
egertonwarburton
elabor
goal
global
health
invest
fund
ghif
invest
qualiti
support
latestag
clinic
trial
earlystag
commercialis
vaccin
drug
diagnost
devic
requir
control
infecti
diseas
lowincom
countri
world
bank
classif
exampl
invest
eubiolog
manufactur
facil
oral
cholera
vaccin
prequalifi
decemb
testifi
impact
financi
support
start
manufactur
egertonwarburton
note
new
innov
financ
mechan
complement
newlypropos
revolv
fund
unicef
may
requir
support
immunis
nongavi
countri
larg
portfolio
new
vaccin
develop
manufactur
develop
countri
confer
focus
novel
relev
result
due
time
limit
precioso
director
clinic
trial
pharmacovigil
butantan
review
clinic
develop
live
attenu
dengu
vaccin
tetraval
vaccin
expect
protect
dengu
serotyp
induc
humor
cellular
immun
respons
requir
one
two
dose
provid
lifelong
immun
phase
clinic
trial
us
nih
show
one
dose
vaccin
safe
immunogen
seroposit
adult
butantan
current
final
phase
ii
clinic
trial
ethic
regulatori
approv
phase
iii
trial
brazil
underway
ht
pham
ceo
bionetasia
outlin
develop
recombin
pertussi
vaccin
respons
resurg
pertussi
around
world
bionet
construct
new
proprietari
bordetella
pertussi
strain
produc
nontox
geneticallyinactiv
pertussi
toxin
rpt
phase
iii
clinic
trial
rptcontain
vaccin
safe
immunogen
healthi
adult
elicit
significantli
higher
antipt
titr
convent
dtap
vaccin
anoth
phase
studi
soon
evalu
rpt
vaccin
epicutan
deliveri
system
l
shi
ceo
shanghai
zerun
biotech
summaris
progress
made
recombin
hpv
vaccin
develop
review
strong
causal
relationship
hpv
infect
cervic
cancer
zerun
bival
hpv
recombin
vaccin
candid
produc
yeast
pichia
pastori
current
phase
iii
clinic
trial
expect
chines
market
obtain
pq
thereaft
addit
novel
recombin
hpv
vaccin
candid
base
escherichia
coli
express
system
develop
anoth
manufactur
china
also
phase
clinic
trial
previous
report
l
castellobranco
scientif
director
ataulpho
de
paiva
fap
present
overview
bcg
vaccin
moreau
substrain
vaccin
develop
brazil
use
oral
vaccin
nation
program
immunis
genet
data
show
substrain
similar
japanes
russian
substrain
safeti
efficaci
intraderm
bcgmoreau
vaccin
demonstr
larg
clinic
trial
bcg
administ
babi
born
hiv
posit
mother
brazil
licens
use
intraves
therapi
bladder
cancer
fap
expand
manufactur
capac
suppli
bcg
global
g
liao
describ
develop
sabin
ipv
institut
medic
biolog
chines
academi
medic
scienc
imbcam
acceler
erad
circul
poliovirus
live
polio
vaccin
launch
initi
develop
ipv
imbcam
start
sabinipv
develop
success
phase
iii
clinic
trial
complet
march
world
first
sabinipv
vaccin
launch
chines
market
juli
imbcam
plan
increas
product
capac
current
million
million
dose
per
annum
develop
combin
vaccin
obtain
pq
enabl
global
suppli
k
ella
bharat
biotech
present
chikungunya
vaccin
inactiv
wholevirion
chikv
deriv
indian
isol
chikv
establish
high
titr
vero
cell
preclin
toxic
studi
demonstr
safeti
time
dose
propos
phase
test
phase
dose
rang
base
compar
studi
protect
correl
convalesc
patient
data
immunogen
test
laboratori
anim
phase
studi
propos
india
vaccin
methodolog
protect
patent
sever
countri
bottazzi
sabin
vaccin
institut
review
novel
technolog
vaccin
neglect
tropic
diseas
seventeen
tropic
diseas
includ
leprosi
trematodiasi
leishmaniasi
dengu
chaga
diseas
filariasi
helminth
infect
highli
preval
among
poor
endem
countri
affect
billion
peopl
sabin
vaccin
institut
focus
product
develop
partnership
develop
effect
lowcost
vaccin
human
hookworm
vaccin
initi
illustr
effort
lead
caus
matern
childhood
anaemia
afflict
million
peopl
two
candid
vaccin
manufactur
current
test
brazil
gabon
institut
seek
partnership
manufactur
develop
countri
advanc
product
clinic
develop
variou
candid
vaccin
eubiolog
oral
cholera
vaccin
ocv
present
park
eubiolog
contract
manufactur
agreement
ivi
product
suppli
cholera
vaccin
sinc
invest
green
cross
corpor
ghif
other
support
project
goal
maintain
milliondos
global
stockpil
thereaft
gradual
increas
million
dose
annual
financ
gavi
stockpil
expect
aid
global
respons
outbreak
improv
overal
avail
suppli
ocv
attract
new
manufactur
incentiv
new
develop
clinic
trial
complet
august
vaccin
approv
korea
prequalif
dossier
approv
demonstr
impact
partnership
among
manufactur
deliveri
ocv
discuss
j
use
recombin
technolog
platform
produc
potenti
world
commercialis
hpv
vaccin
finlay
develop
pneumococc
vaccin
verez
note
world
infant
yet
vaccin
pneumococc
diseas
may
use
afford
vaccin
protect
region
diseas
strain
wait
higher
valenc
vaccin
becom
access
middl
lowincom
popul
headtohead
studi
may
help
understand
impact
multival
vaccin
compar
region
relev
formul
leroy
ask
manufactur
innovax
could
acceler
pq
dcvmn
member
could
support
clinic
develop
huang
state
dcvmn
abl
break
barrier
countri
facilit
collabor
knowledg
share
matter
call
initi
harmonis
qualiti
clinic
trial
dcvmn
role
call
converg
regul
encourag
precioso
comment
dcvmn
sever
initi
includ
workshop
clinic
trial
manag
harmonis
practic
support
prequalif
vaccin
dcvmn
need
time
develop
complex
initi
collabor
compani
contribut
enabl
jointclin
develop
intern
multicentr
clinic
trial
curri
centr
vaccin
ethic
polici
whose
expertis
lie
ethic
legal
requir
oversight
clinic
trial
suggest
one
area
support
dcvm
might
develop
ethic
framework
guid
clinic
trial
design
conduct
assess
discuss
vaccin
secur
moder
j
kim
director
gener
ivi
h
deehan
unicef
makhoana
biovac
n
premsri
mahmoud
contributor
unicef
gavi
steadili
increas
vaccin
fund
procur
develop
countri
respons
increas
demand
h
deehan
note
sourc
vaccin
multipl
supplier
help
prevent
global
vaccin
shortag
also
creat
fierc
competit
note
difficulti
find
balanc
ideal
number
supplier
foster
sustain
competit
market
kim
turn
attent
recent
ebola
outbreak
africa
brought
control
without
vaccin
pose
question
manufactur
prepar
reemerg
makhoana
agre
futur
outbreak
may
come
emphasis
understand
infecti
agent
must
preced
product
develop
vaccin
need
part
broader
strengthen
health
system
ultim
respons
tackl
african
diseas
may
need
come
within
africa
kim
queri
vaccin
secur
asia
context
region
threat
bird
flu
sar
mer
n
premsri
relat
thailand
philosophi
selfreli
ideal
capac
produc
essenti
vaccin
adequ
stockpil
multipl
region
manufactur
order
respond
outbreak
shortag
mahmoud
describ
vaccinesuppli
challeng
saudi
arabia
object
high
vaccin
coverag
undermin
vaccin
shortag
lack
expertis
vaccin
manufactur
region
technolog
transfer
appropri
partner
compet
team
manufactur
acceler
effort
secur
high
vaccin
coverag
region
discuss
develop
market
moder
j
chu
senior
director
vaccin
market
clinton
health
access
initi
chai
note
vaccin
market
uniqu
requir
high
invest
manufactur
lengthi
develop
time
often
result
unintent
suppli
monopoli
chang
regulatori
standard
caus
disrupt
delay
lot
releas
registr
despit
challeng
dcvmn
member
contribut
significantli
increas
access
vaccin
global
humanvaccin
market
estim
us
billion
forecast
reach
us
billion
seiz
opportun
compet
success
rapidli
grow
global
market
manufactur
need
continu
innov
malham
gavi
rais
balanc
afford
sustain
vaccin
suppli
explain
gavi
evalu
new
vaccin
pass
phase
ii
clinic
trial
inclus
vaccin
portfolio
financ
gavi
evalu
datadriven
includ
paramet
diseas
burden
feasibl
costeffect
diseas
prevent
howev
note
coordin
align
global
stakehold
need
improv
ensur
develop
need
vaccin
also
comment
high
cost
vaccin
develop
rel
drug
diagnost
could
overcom
part
technolog
improv
manufactur
process
k
ella
bharat
biotech
share
insight
build
success
intern
partnership
balanc
privat
public
contribut
privatis
manufactur
result
stabl
vaccin
suppli
mani
countri
privat
enterpris
enhanc
suppli
publicsector
l
shi
zerun
institut
walvax
discuss
corpor
motiv
enter
intern
market
also
serv
need
domest
market
walvax
priorit
productportfolio
invest
allow
suppli
vaccin
intern
larg
manufactur
capac
requir
satisfi
domest
intern
market
mani
chines
compani
capac
thu
world
like
see
vaccin
chines
manufactur
futur
f
lobo
describ
sinergium
journey
vaccin
market
south
america
sinergium
spinoff
veterinarian
vaccin
manufactur
establish
technolog
transfer
agreement
larg
multin
primarili
satisfi
nation
need
influenza
pneumococc
hpv
vaccin
importantli
partnership
govern
acceler
progress
technic
support
receiv
local
regulatori
agenc
build
worldclass
facil
compli
intern
standard
also
multiyear
government
suppli
contract
secur
stabil
compani
local
intern
partner
critic
rapid
success
modern
facil
equip
compani
aim
expand
partnership
dcvm
ingli
director
nibsc
moder
panel
includ
jadhav
serum
institut
india
batson
path
p
carrasco
iaim
k
sampson
apaci
trust
vaccin
jadhav
describ
experi
serum
institut
india
one
largest
success
manufactur
emerg
countri
whoprequalifi
vaccin
still
reluct
purchas
product
develop
countri
basi
perceiv
higher
reactogen
prefer
known
brand
barrier
accept
new
product
measl
vaccin
prequalifi
howev
unicef
immedi
take
serum
institut
suppli
measlescontain
vaccin
use
achiev
measl
rubella
erad
latin
america
introduct
mening
vaccin
african
countri
commun
leader
inform
benefit
result
high
accept
success
prevent
diseas
lesson
industri
need
invest
consider
effort
inform
stakehold
product
intent
batson
note
vaccin
hesit
often
specif
countri
situat
rather
global
issu
strongli
agre
engag
local
commun
leader
signific
impact
uptak
interestingli
mobil
phone
proven
use
advoc
vaccin
teenag
hpv
vaccin
k
sampson
discuss
confid
influenza
vaccin
risk
strain
make
vaccin
may
fulli
match
caus
diseas
due
antigen
drift
note
asia
larg
ethnic
sociocultur
heterogen
popul
vaccin
may
suit
patient
decisionmak
influenza
vaccin
driven
whether
like
protect
vaccin
individu
also
whether
like
help
protect
other
herd
immun
readi
avail
diseas
data
commun
medic
profession
would
assist
highlight
valu
p
carrasco
elabor
role
health
worker
deliv
vaccin
note
build
patient
trust
impart
knowledg
vaccin
vaccin
also
inspir
confid
clearli
trust
intervent
educ
program
organis
profession
associ
need
provid
health
profession
right
inform
vaccin
use
languag
new
tool
smart
phone
within
reach
health
worker
even
lowincom
countri
dcvmn
annual
gener
meet
gave
rich
insight
advanc
vaccin
technolog
develop
new
vaccin
provid
valuabl
opportun
vaccin
manufactur
regulatori
author
intern
organis
facetofac
interact
achiev
global
immunis
local
author
commun
leader
play
import
role
decisionmak
vaccin
introduct
uptak
base
abil
vaccin
protect
vaccin
peopl
protect
nonvaccin
commun
herd
immun
reduc
risk
vaccin
shortag
achiev
increas
regulatori
converg
region
intern
level
combat
prevent
diseas
outbreak
remain
challeng
collect
effort
improv
multicentr
clinic
trial
includ
variou
popul
creat
region
relev
vaccin
manufactur
stockpil
secur
strategi
foster
stabl
vaccin
market
procur
build
trust
vaccin
recommend
approach
dcvmn
member
continu
collabor
one
anoth
partner
regul
toward
goal
improv
global
access
immunis
sustain
suppli
vaccin
match
demand
well
greater
capac
rapidli
respond
outbreak
aim
provid
high
qualiti
vaccin
peopl
